.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX02_Asparaginase.Asparaginase_2 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX02_Asparaginase.Asparaginase_2| name: | Asparaginase_2 |
| ATC code: | L01XX02_2 | route: | intravenous |
| n-compartments | 1 |
Asparaginase is an enzyme used as an antineoplastic agent primarily in the treatment of acute lymphoblastic leukemia (ALL). It works by depleting the amino acid asparagine, which leukemia cells are unable to synthesize, thereby inhibiting their growth. Asparaginase is approved and in use, especially as a part of multiagent chemotherapy protocols for pediatric and adult ALL.
Pharmacokinetic parameters for Erwinia asparaginase (crisantaspase) in pediatric patients with ALL who developed hypersensitivity to E. coli-derived asparaginase, following intravenous administration of 25,000 IU/m2.
Sassen, SD, et al., & van der Sluis, IM (2017). Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. Haematologica 102(3) 552–561. DOI:10.3324/haematol.2016.149195 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28250007
Würthwein, G, et al., & Boos, J (2021). Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data. European journal of drug metabolism and pharmacokinetics 46(2) 289–300. DOI:10.1007/s13318-021-00670-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33595793
Völler, S, et al., & Hempel, G (2018). Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia. Cancer chemotherapy and pharmacology 81(2) 305–314. DOI:10.1007/s00280-017-3492-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29204688